Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

@article{Sorror2005HematopoieticCT,
  title={Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.},
  author={Mohamed L Sorror and Michael B. Maris and Rainer F Storb and Fr{\'e}d{\'e}ric Baron and Brenda M. Sandmaier and David G Maloney and Barry E. Storer},
  journal={Blood},
  year={2005},
  volume={106 8},
  pages={
          2912-9
        }
}
We previously reported that the Charlson Comorbidity Index (CCI) was useful for predicting outcomes in patients undergoing allogeneic hematopoietic cell transplantation (HCT). However, the sample size of patients with scores of 1 or more, captured by the CCI, did not exceed 35%. Further, some comorbidities were rarely found among patients who underwent HCT. Therefore, the current study was designed to (1) better define previously identified comorbidities using pretransplant laboratory data, (2… Expand
A modified comorbidity index for hematopoietic cell transplantation
TLDR
The modified comorbidity index (MCI), which may have higher discriminating and predictive power for overall survival and NRM, is introduced using a cohort of 444 adult allogeneic HCT recipients using a pure multiplicative model. Expand
Hematopoietic cell transplantation comorbidity index predicts transplantation outcomes in pediatric patients.
TLDR
The results indicate that the HCT-CI score predicts NRM and OS in pediatric patients undergoing HCT and is a useful tool to assess risk, guide counseling in the pretransplantation setting, and devise innovative therapies for the highest risk groups. Expand
Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index: a prospective, multicenter GITMO study.
TLDR
HCT-CI alone was the strongest predictor of NRM in patients with lymphoma, myelodysplastic syndrome, and acute myeloid leukemia in first remission, and the clinical utility of the HCT- CI score is confirmed that could also identify patients at low NRM risk possibly benefiting from an HSCT-based treatment strategy. Expand
Treat How I assess comorbidities before hematopoietic cell transplantation
Organ dysfunctions (comorbidities) were found to be associated with the outcome of treatment of a given primary disease and, in particular, cancer. In 2005, a hematopoietic cellExpand
Association of hematopoietic cell transplantation-specific comorbidity index with resource utilization after allogeneic transplantation
TLDR
It is found that HCT-CI >0 to 1 is associated with increased RU after allogeneic HCT, and recognizing predictors of RU can identify patients at risk of high utilization and help understand what drives health-care costs. Expand
Impact of comorbidity indexes on non-relapse mortality
TLDR
Comorbidity indexes have been reported to predict non-relapse mortality (NRM) and overall survival after allogeneic hematopoietic stem cell transplantation (HSCT) but the discriminative properties of the three CIs were rather low in this population. Expand
Age adjusted hematopoietic stem cell transplant comorbidity index predicts survival in a T-cell depleted cohort.
TLDR
Despite a small sample population, HCT-CI/Age was more discriminative to identify patients with poor outcome that might benefit from intensified management strategies or other therapeutic approaches rather than allogeneic HCT. Expand
Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation.
  • M. Sorror, R. Storb, +12 authors B. Storer
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2014
TLDR
The proposed composite measure allows integration of both comorbidities and age into clinical decision making and comparative-effectiveness research of HCT and shows age is a poor prognostic factor. Expand
Role of Comorbidities in Optimizing Decision-Making for Allogeneic Hematopoietic Cell Transplantation
  • M. Sorror, R. Storb
  • Medicine
  • Mediterranean journal of hematology and infectious diseases
  • 2010
TLDR
The usefulness of the HCT-CI in predicting HCT outcomes in patients with myeloid and lymphoid malignancies undergoing allogeneic transplantation is illustrated. Expand
Assessing the Influence of Different Comorbidities Indexes on the Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in a Developing Country
TLDR
The results show that, in the population studied, none of the comorbidity indexes seem to be associated with AHSCT outcomes, and a significantly low frequency of high-risk HCT-CI ≥ 3 in this Brazilian population might justify these results. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 70 REFERENCES
Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities.
TLDR
Even though nonablative patients had significantly higher pretransplantation comorbidity scores, were older, and had more often failed preceding ablative transplantations and cytotoxic therapies, they experienced fewer grades III to IV toxicities than ablative patients. Expand
Prognostic importance of comorbidity in a hospital-based cancer registry.
TLDR
Comorbidity is an important independent prognostic factor for patients with cancer and the inclusion of comorbidities in hospital-based cancer registries will increase the value and use of observational research. Expand
Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
  • F. Baron, M. Maris, +9 authors R. Storb
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
TLDR
New approaches aimed at reducing the incidence of grade 2 to 4 acute GVHD might improve survival after allogeneic HCT after nonmyeloablative conditioning. Expand
Adapting the Charlson Comorbidity Index for use in patients with ESRD.
TLDR
This study indicates that the original Charlson index is a valid tool to assess comorbidity and predict survival in patients with end-stage renal disease, however, the modified ESRD com orbidity index had slightly better performance characteristics in this population. Expand
Prognostic Relevance of “Early-Onset” Graft-Versus-Host Disease Following Nonmyeloablative Hematopoietic Cell Transplantation.
TLDR
Early-onset GVHD (prednisone initiation before day 50) was associated with increased NRM and poor survival after nonmyeloablative HCT from HLA-identical related donors and identified a subgroup of patients who might benefit from more aggressive primary therapy of GV HD. Expand
The prognostic importance of comorbidity for mortality in patients with stable coronary artery disease.
TLDR
Comorbid disease is strongly associated with long-term survival in patients with CAD and co-existing illnesses should be measured and considered in clinical trials, disease registries, quality comparisons, and counseling of individual patients. Expand
Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation
TLDR
Pretransplant risk factors are cumulative for individual patients with CML having blood or marrow transplantation, and a simple system based on five main factors gives adequate risk assessment for counselling of patients and taking decisions. Expand
Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia.
  • M. Sorror, M. Maris, +17 authors D. Maloney
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
TLDR
CLL is susceptible to graft-versus-leukemia effects, and allogeneic HCT after nonmyeloablative conditioning might prolong median survival for patients with advanced CLL. Expand
The Impact of Comorbidity and Age on Survival with Laryngeal Cancer
TLDR
It is concluded that the CCI is a strong predictor of survival inpatients with laryngeal cancer and the confounding effects of comorbidity should be considered in the TNM staging of larynGEal cancer to improve the prognostic ability. Expand
[Does Charlson-comorbidity index correlate with short-term outcome in patients with gastric cancer?].
TLDR
The CCI was found not to be a valid prognostic indicator in gastric cancer and the method of classifying comorbidity by CCI provides a simple, readily applicable and valid method of estimating risk of death fromComorbid disease for use in longitudinal studies and in outcomes research from administrative databases. Expand
...
1
2
3
4
5
...